References
- Inman W. H. W., Vessey M. P., Westerholm B., Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives ‐ a report to the Committee on Safety of Drugs. Br. Med. J. 1970; 2: 203–9
- Royal College of General Practitioners Oral Contraceptives Study. Oral contraceptives, venous thrombosis, and varicose veins. J. R. Coll. Gen. Pract. 1978; 28: 393–9
- Notelovitz M. Oral contraception and coagulation. Clin. Obstet. Gynecol. 1985; 28: 73–83
- Beller F. K., Ebert C. Effects of oral contraceptives on blood coagulation. A review. Obstet. Gynecol. Surv. 1985; 40: 425–36
- Mammen E. F. Oral contraceptives and blood coagulation: a critical review. Am. j. Obstet. Gynecol. 1982; 142: 781–90
- Winkler U. H., Buhler K., Oberhoff C., Koslowski S., Hölscher T., Goitowski S., Rehage B., Schindler A. E. The dynamic balance of hemostasis: a key for understanding thromboembolism in oral contraceptive users. Current Research in Gynecology and Obstetrics, A. R. Genazzani. Parthenon Publishing, Camforth 1991; 389–94
- Vandenbroucke J. P., Koster T., Briet E., Reitsma P. H., Bertina K. M., Rosendaal F. R. Increased risk of venous thrombosis in oral‐contraceptive users who are carriers of Factor V Leiden mutation. Lancet 1994; 344: 1453–7
- Pabinger I., Schneider B., The GTH Study Group on Natural Inhibitors. Thrombotic risk of women with hereditary antithrombin III‐, protein C‐ and protein S‐deficiency taking oral contraceptive medication. Thromb. Haemost. 1994; 71: 548–52
- Schafer A. I. The hypercoagulate states. Ann. Intern. Med. 1985; 102: 814–28
- Bauer K. A., Rosenberg R. D. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343–50
- Mammen E. F., Fujii Y. Hypercoagulate states. Lab. Med. 1989; 1: 611–16
- Melis G. B., Fruzzeti F., Nicoletti I., Ricci C., Lammers P., Atsma W. J., Fioretti P. A comparative study on the effects of a monophasic pill containing desogestrel plus 20 μg ethinylestradiol, a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulatory factors. Contraception 1991; 43: 23–31
- Daly I., Bonnar J. Comparative studies of 30 μg ethinyl estradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis and platelets. Am. j. Obstet. Gynecol. 1990; 163: 430–7
- Bonnar J., Daly L., Carroll E. Blood coagulation with a combination pill containing gestodene and ethinylestradiol. Int. J. Fertil. 1987; 32: 21–8
- Winkler U. H., Koslowski S., Oberhoff C., Schindler E. M., Schindler A. E. Changes of dynamic equilibrium of hemostasis associated with the use of low‐dose oral contraceptives: a controlled study of cyproterone acetate containing oral contraceptives combined with either 35 or 50 μg ethinyl estradiol. Adv. Contra‐cept. 1991; 7: 273–84
- Basedevant A., Conard J., Pelissier C., Guyene T. T., Lapousterle C., Mayer M., Gy‐Grand B., Degrelle H. Hemostatic and metabolic effects of lowering the ethinyl‐estradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrel. Contraception 1991; 48: 193–202
- Gerstman B. B., Piper J. M., Tomita D. K., Ferguson W. J., Stadel B. V., Lundin F. E. Oral contraceptives estrogen dose and the risk of deep venous thromboembolic disease. Am. J. Epidemiol. 1991; 177: 32–7
- Lidegaard O. Oral contraception and risk of cerebral thromboembolic attack: results of a case—control study. Br. Med. J. 1993; 306: 956–63
- Trauchst‐Van Horn J. J., Capeless E. L., Easterling T. R., Bovill E. G. Pregnancy loss and thrombosis with protein C deficiency. Am. J. Obstet. Gynecol. 1992; 167: 9968–72
- Briet E., van der Meer F. J. M., Rosendaal F. R., Houwing‐Duistermaat J. J., van Houwelingen J. C. The family history and inherited thrombophilia. Br. J. Haematol. 1994; 87: 348–52
- Winkler U. H. Stellungnahme Zuni Be‐scheid des Bundesgesundheitsanites vom 7.12.92 zur Änderung der Packungsbcilage bei oralen Kon‐trazeptiva. Der Frauenarzt. 1993; 34: 234–6
- Comp P. C., Zacur H. A. Contraceptive choices in women with coagulation disorders. Am. J. Obstet. Gynecol. 1993; 168: 2042–8
- Jespersen J., Petersen K. R., Skouby S. O. Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid. Am. J. Obstet. Gynecol. 1990; 163: 396–403